on May 15, 2006
Published online before print May 15, 2006, doi: 10.1161/CIRCULATIONAHA.105.594077
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 14, 2005
From the Department of Obstetrics and Gynecology (S.L.H.), Wayne State University School of Medicine/Hutzel Women’s Hospital, Detroit, Mich; The Albert Einstein College of Medicine (S.W.-S.), Bronx, NY; Department of Preventive Medicine (K.C.J.), University of Tennessee Health Science Center, Memphis, Tenn; MedStar Research Institute (B.V.H.), Washington, DC; Fred Hutchinson Cancer Research Center (C.K., A.A.), Seattle, Wash; National Heart, Lung, and Blood Institute (J.E.R.), Bethesda, Md; State University of New York (M.T.), Buffalo, NY; National Institute of Neurological Disorders and Stroke, Stroke Neuroscience Unit (A.E.B.) and Neuroepidemiology Branch (J.K.L.), Bethesda, Md; Baylor College of Medicine (P.F.B.), Houston, Tex; Harvard Medical School (J.E.B.), Boston, Mass; University of California at San Diego (M.H.C.), La Jolla, Calif; Wake Forest University Health Sciences (D.H., S.R.R.), Winston-Salem, NC; and Department of Epidemiology (J.T.), University of Iowa College of Public Health, Iowa City, Iowa. * To whom correspondence should be addressed. E-mail: shendrix{at}med.wayne.edu.
Background--The Women’s Health Initiative (WHI) Estrogen Alone trial assessed the balance of benefits and risks of hormone use in healthy postmenopausal women. The trial was stopped prematurely because there was no benefit for coronary heart disease and an increased risk of stroke. This report provides a thorough analysis of the stroke finding using the final results from the completed trial database. Methods and Results--The WHI Estrogen Alone hormone trial is a multicenter, double-blind, placebo-controlled, randomized clinical trial in 10 739 women aged 50 to 79 years who were given daily conjugated equine estrogen (CEE; 0.625 mg; n=5310) or placebo (n=5429). During an average follow-up of 7.1 years, there were 168 strokes in the CEE group and 127 in the placebo group; 80.3% of strokes were ischemic. For all stroke the intention-to-treat hazard ratio [HR] (95% CI) for CEE versus placebo was 1.37 (1.09 to 1.73). The HR (95% CI) was 1.55 (1.19 to 2.01) for ischemic stroke and 0.64 (0.35, 1.18) for hemorrhagic stroke. The HRs indicate excess risk of ischemic stroke was apparent in all categories of baseline stroke risk, including younger and more recently menopausal women and in women with prior or current use of statins or aspirin. Conclusions--CEE increases the risk of ischemic stroke in generally healthy postmenopausal women. The excess risk appeared to be present in all subgroups of women examined, including younger and more recently menopausal women. There was no convincing evidence to suggest that CEE had an effect on the risk of hemorrhagic stroke.
Revised on March 17, 2006
Accepted on March 21, 2006
Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative
Susan L. Hendrix DO*,
Key words: women • stroke • hormones • estrogen
This article has been cited by other articles:
 |
|
 |
|
  R. D. Langer Efficacy, Safety, and Tolerability of Low-Dose Hormone Therapy in Managing Menopausal Symptoms J Am Board Fam Med, September 1, 2009; 22(5): 563 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Prentice, J. E. Manson, R. D. Langer, G. L. Anderson, M. Pettinger, R. D. Jackson, K. C. Johnson, L. H. Kuller, D. S. Lane, J. Wactawski-Wende, et al. Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause Am. J. Epidemiol., July 1, 2009; 170(1): 12 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and E. T. Hawk Cancer Prevention: From 1727 to Milestones of the Past 100 Years Cancer Res., July 1, 2009; 69(13): 5269 - 5284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Drospirenone in HRT? DTB, April 1, 2009; 47(4): 41 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hsia, J. C Larson, J. K Ockene, G. E Sarto, M. A Allison, S. L Hendrix, J. G Robinson, A. Z LaCroix, J. E Manson, and for the Women's Health Initiative Research Group Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study BMJ, February 3, 2009; 338(feb03_2): b219 - b219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhao, Z. Mao, and R. D. Brinton A Select Combination of Clinically Relevant Phytoestrogens Enhances Estrogen Receptor {beta}-Binding Selectivity and Neuroprotective Activities in Vitro and in Vivo Endocrinology, February 1, 2009; 150(2): 770 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 WRITING GROUP MEMBERS, D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T. B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, et al. Heart Disease and Stroke Statistics--2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, January 27, 2009; 119(3): e21 - e181. [Full Text] [PDF]
|
|
|
|
|
|
Herbal medicines for menopausal symptoms DTB, January 1, 2009; 47(1): 2 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. S. Gass, S. S. Bassuk, and J. E. Manson Reassessing Benefits and Risks of Hormone Therapy American Journal of Lifestyle Medicine, January 1, 2009; 3(1): 29 - 43. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Mosca, D. Grady, E. Barrett-Connor, P. Collins, N. Wenger, B. L. Abramson, A. Paganini-Hill, M. J. Geiger, S. A. Dowsett, M. Amewou-Atisso, et al. Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease Stroke, January 1, 2009; 40(1): 147 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zhan, T. Keimig, J. Xu, E. Peterson, J. Ding, F. Wang, and X.-P. Yang Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction Exp Physiol, August 1, 2008; 93(8): 982 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Vagnerova, I. P. Koerner, and P. D. Hurn Gender and the Injured Brain Anesth. Analg., July 1, 2008; 107(1): 201 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Bushnell, J. Lee, P. W. Duncan, L. K. Newby, and L. B. Goldstein Impact of Comorbidities on Ischemic Stroke Outcomes in Women Stroke, July 1, 2008; 39(7): 2138 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Prentice, R. T. Chlebowski, M. L. Stefanick, J. E. Manson, R. D. Langer, M. Pettinger, S. L. Hendrix, F. A. Hubbell, C. Kooperberg, L. H. Kuller, et al. Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study Am. J. Epidemiol., June 15, 2008; 167(12): 1407 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein, J. E. Manson, M. J. Stampfer, and K. Rexrode Postmenopausal Hormone Therapy and Stroke: Role of Time Since Menopause and Age at Initiation of Hormone Therapy Arch Intern Med, April 28, 2008; 168(8): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassertheil-Smoller, C. Kooperberg, A. P. McGinn, R. C. Kaplan, J. Hsia, S. L. Hendrix, J. E. Manson, J. S. Berger, L. H. Kuller, M. A. Allison, et al. Lipoprotein-Associated Phospholipase A2, Hormone Use, and the Risk of Ischemic Stroke in Postmenopausal Women Hypertension, April 1, 2008; 51(4): 1115 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Group Members, W. Rosamond, K. Flegal, K. Furie, A. Go, K. Greenlund, N. Haase, S. M. Hailpern, M. Ho, V. Howard, et al. Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, January 29, 2008; 117(4): e25 - e146. [Full Text] [PDF]
|
|
|
|
|
|
J. Bourghardt, G. Bergstrom, A. Krettek, S. Sjoberg, J. Boren, and A. Tivesten The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice Endocrinology, September 1, 2007; 148(9): 4128 - 4132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Career in Pharmacology: In Search of Beauty and Joy Mol. Interv., August 1, 2007; 7(4): 183 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]
|
|
|
|
 |
|
 J. E. Rossouw, R. L. Prentice, J. E. Manson, L. Wu, D. Barad, V. M. Barnabei, M. Ko, A. Z. LaCroix, K. L. Margolis, and M. L. Stefanick Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause JAMA, April 4, 2007; 297(13): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Rosamond, K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. Haase, M. Ho, V. Howard, B. Kissela, et al. Heart Disease and Stroke Statistics--2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, February 6, 2007; 115(5): e69 - e171. [Full Text] [PDF]
|
|
|
|
 |
|
 H. L Thacker Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk Evid. Based Med., December 1, 2006; 11(6): 178 - 178. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Chappell, L. M. Yamaleyeva, and B. M. Westwood Estrogen and salt sensitivity in the female mRen(2).Lewis rat Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1557 - R1563. [Abstract] [Full Text] [PDF]
|
|